NFE2L2 and prostate cancer: It is reported that EZH2 downregulation in lung cancer leads to the reduction of H3K27me3 at NRF2 promoter area and increases NRF2 transcription eventually (Li et al., 2014), whereas SetD7 can activate the antioxidant NRF2/KEAP1 pathway by elevating H3K4 methylation in prostate cancer cells (Wang et al., 2018a).